about
Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection andMechanisms of drug resistance: daptomycin resistanceImportance of relating efficacy measures to unbound drug concentrations for anti-infective agentsEvaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection.Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients.Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.Evaluation of Daptomycin Non-Susceptible Staphylococcus aureus for Stability, Population Profiles, mprF Mutations, and Daptomycin ActivityPopulation dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments.Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.In vivo pharmacodynamics of new lipopeptide MX-2401Staphylococcus aureus in continuous culture: a tool for the rational design of antibiotic treatment protocolsUse of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?An optimized mouse thigh infection model for enterococci and its impact on antimicrobial pharmacodynamics.Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteersIn vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant.A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections.Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms.In vivo pharmacodynamic activity of the glycopeptide dalbavancinDaptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus.Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.Daptomycin - a novel antibiotic against Gram-positive pathogens.Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics.In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents.Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coliComparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia modelEvaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience.Update on daptomycin: the first approved lipopeptide antibiotic.Correlation of cell membrane lipid profiles with daptomycin resistance in methicillin-resistant Staphylococcus aureus.Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysisEvaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice.Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections.In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteersDaptomycin: a review 4 years after first approval.
P2860
Q24643277-3DC9A7BC-4E94-4C0A-8844-1AFB6CF83959Q26779944-8A687D6B-AC03-4054-8E7F-293AEA1371D6Q26827380-2142F4E4-CAD3-4B09-B391-EE57340EDE31Q33239640-8BD46A9F-D596-406F-BC15-74C955209281Q33518268-8F8E9F7B-284E-4894-9027-ED8BAED884ECQ33883648-AE8C735E-886B-4C4A-9FD2-B9ACB1ECBE4AQ33939055-7EF537A0-FB78-4026-BB88-5F14F024BFAEQ34045319-246126B0-51B5-4687-91D9-DAFA603076FAQ34150994-F00F696B-48E3-4E55-BE82-381B26D3F15AQ34274190-429C959E-1B77-43FE-9745-D8A84617DD8BQ34309486-75CF0DEC-AD48-4C3F-A52B-59FC3D417554Q34387384-14F30A69-2918-4F82-8875-BDBEC1531E8DQ34737743-2D16E9E4-7E20-41A5-82F0-93A2113EC146Q34894900-7C131FBA-C09D-4815-8AB5-5384E8C68BC6Q34922257-6127987D-B469-41CF-98A8-D2B00958594CQ34926950-076E43D1-A552-44EA-8B41-50BB072B26C3Q35091557-56A0B74E-0D2E-439F-A71C-A1555BD163DEQ35105932-24AF7F51-CB3A-411E-AAEE-3AE5BF80B185Q35139518-AADBBD1C-EF7C-4084-8BE0-7EA7FB140565Q35166807-8FCC0669-631A-45F8-A6DD-198F260AEC8EQ35191390-23C2CA25-9182-42CC-8471-B71A7B33754FQ35759076-8AE9D10C-A7FD-46AC-9D24-5DB53A1B5E22Q35771368-D21A9D42-D166-46C0-8B96-C7CBC1CFA6EAQ35912780-C9281AAB-ABBA-4414-8E5B-3BB577CAD907Q35925535-9AE78BF9-3E85-44C6-B5EE-439A6E703D34Q35941248-97B6BB97-8B6B-4ACA-B3A8-6AE52E833A6BQ35941284-1C522518-ED78-4D89-A0BE-912A3002C453Q36162355-E3849CC5-9517-4A19-ADE3-94FEFC8605BAQ36171670-82B4C4DC-86CD-4F3B-AC6F-797D52FAE508Q36364009-A0FC4FBA-0D6F-410D-BC24-183A49244290Q36373724-F73326A0-6EB2-47E8-A621-F6333A86E8B4Q36521880-71FE3AEE-A361-43B7-AABC-0742E73F4567Q36558432-EF0FA871-5C6E-4EF8-A54F-6474CDA43437Q36558512-EDB5AB22-BB66-460E-8A5C-101B17C57BE1Q36644902-4C2918E5-18AF-48B8-A065-C207CDF6E9E4Q36666985-5923831E-A438-4BA4-9B7D-68EC9C6BC0C1Q36686882-6B52FD75-A998-4D3D-AB57-93116F3CECE1Q36888137-B0ABC25B-10A2-4925-B1B5-F1C4B13774B4Q36949468-1CFD42D9-AF9E-4092-95DA-CBA79693F765Q36972980-6FAF707C-C1A5-4866-9809-A88668B0580C
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
In vivo pharmacodynamic activity of daptomycin
@ast
In vivo pharmacodynamic activity of daptomycin
@en
type
label
In vivo pharmacodynamic activity of daptomycin
@ast
In vivo pharmacodynamic activity of daptomycin
@en
prefLabel
In vivo pharmacodynamic activity of daptomycin
@ast
In vivo pharmacodynamic activity of daptomycin
@en
P2860
P1476
In vivo pharmacodynamic activity of daptomycin
@en
P2093
Nasia Safdar
P2860
P356
10.1128/AAC.48.1.63-68.2004
P407
P50
P577
2004-01-01T00:00:00Z